Actively Recruiting
Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer
Led by China Medical University Hospital · Updated on 2026-03-24
48
Participants Needed
1
Research Sites
265 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Previous studies found that some NMDA-enhancing agents were able to improve clinical symptoms of patients with schizophrenia. Whether treatment of an NMDA-enhancing agent can benefit the treatment of prodromal schizophrenia deserves study.
CONDITIONS
Official Title
Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Individuals meeting Criteria of Prodromal Syndrome (at least one of the following: 1. attenuated positive symptoms; 2. brief intermittent psychotic symptoms; 3. genetic risk and deterioration).
- Subjects remain symptomatic (scoring at least 20 on the Scale of Prodromal Symptoms [SOPS] total score) after the 6-week screening phase (which contains the health-promotion program) and before the 12-week drug-trial period.
- Subjects may be receiving ongoing treatment with antipsychotic medications, or may be medication-free for at least 12 weeks.
- For subjects already on antipsychotics, they must have been on a stable dose for at least 4 weeks before screening and keep doses unchanged during the study.
- For subjects not on antipsychotics, these medications are forbidden during the study.
- Subjects agree to participate and provide written informed consent; for participants under 20 years old, a parent must also provide consent.
You will not qualify if you...
- DSM-5 diagnosis of intellectual disability, substance (including alcohol) use disorder, schizophrenia, schizophreniform disorder, delusional disorder, schizoaffective disorder, substance/medication-induced psychotic disorder, or psychotic disorder due to another medical condition.
- History of epilepsy, head trauma, stroke, or serious medical or central nervous system diseases (other than schizophrenia) that may interfere with the study.
- Clinically significant abnormal laboratory screening tests (blood routine, biochemical tests).
- Pregnancy or lactation.
- Inability to follow the study protocol.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Psychiatry, China Medical University Hospital
Taichung, Taiwan
Actively Recruiting
Research Team
H
Hsien-Yuan Lane, M.D., Ph.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here